PANTOZOL IV

국가: 인도네시아

언어: 인도네시아어

출처: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

유효 성분:

PANTOPRAZOLE SODIUM SESQUIHYDRATE

제공처:

TAKEDA INDONESIA - Indonesia

INN (국제 이름):

PANTOPRAZOLE SODIUM SESQUIHYDRATE

복용량:

45.1 MG

약제 형태:

SERBUK INJEKSI

패키지 단위:

DUS, 1 VIAL @ 40 MG

Manufactured by:

TAKEDA GMBH - Federal Republic of Germany

승인 날짜:

2020-12-17

제품 특성 요약

Insert leaflet
Pantozol
®
i.v.
ACTIVE INGREDIENT:
PANTOPRAZOLE SODIUM SESQUIHYDRATE
COMPOSITION
Each vial contains 45.1 mg Pantoprazole sodium
sesquihydrate (equivalent to pantoprazole 40 mg).
PHARMACOLOGICAL PROPERTIES
ATC Code : A02BC02
MECHANISM OF ACTION
Pantoprazole is a substituted benzimidazole which
inhibits the secretion of hydrochloric acid in the
stomach by specific action on the proton pumps of the
parietal cells.
Pantoprazole is converted to its active form in the
acidic environment in the parietal cells where its
inhibits the H+, K+-ATPase enzyme, i.e. the final stage
in the production of hydrochloric acid in the stomach.
The inhibition is dose-dependent and affects both
basal and stimulated acid secretion. As with other
proton pump inhibitors and H2 receptor inhibitors,
treatment with pantoprazole causes a reduced acidity
in the stomach and thereby an increase in gastrin in
proportion to the reduction in acidity. The increase in
gastrin is reversible. Since pantoprazole binds to the
enzyme distal to the cell receptor level, the substance
can affect hydrochloric acid secretion independently
of stimulation by other substances (acetylcholine,
histamine, gastrin). The effect is the same whether
the product is given orally or intravenously.
INDICATIONS
-
Duodenal ulcer
-
Gastric ulcer
-
Moderate and severe cases of inflammation
of the oesophagus (reflux esophagitis)
-
For
the
treatment
of
pathological
hypersecretory
condition
associated
with
Zollinger-Ellison-Syndrome
and
other
neoplastic conditions
POSOLOGY AND METHOD OF ADMINISTRATIONS
The intravenous administration of Pantozol® i.v. is
recommended
only
if
oral
application
is
not
appropriate.
•
RECOMMENDED DOSAGE
Duodenal ulcer, gastric ulcer, moderate and severe
reflux esophagitis
The recommended intravenous dosage is one vial (40
mg pantoprazole) Pantozol® i.v. per day.
Long-term management of Zollinger-Ellison-Syndrome
and other pathological hypersecretory conditions
Patients should start their treatment with a daily dose
of 80 mg Pantozol® i